In The News

What some want to call science is increasingly politics masquerading as science. And nothing has demonstrated that better than the coronavirus. 

Compulsory licensing deters innovators from investing in drug discovery. It won’t reduce what patients pay.

Important legislation has been proposed that would encourage medical and pharmaceutical manufacturing to relocate to the U.S. by providing potent tax incentives instead of threats of government force.

Americans are the world’s top users of generics, but not of biosimilars. State and local governments should encourage a wider uptake for their own employees as an important start—and a much-needed cost savings. 

The job of economic recovery is critical, and the American people are counting on Congress and the Fed to get it done without a political agenda.

Having already entrusted the Fed with hundreds of billions of taxpayer dollars to buy up corporate debt, Congress must insist that the debt purchases be made for exclusively economic reasons.

Because of the superiority of entrepreneurship and free enterprise to government bureaucracy, America’s best days in space are just beginning.

If a shot becomes available, there's a good chance more people will choose to vaccinate without a government mandate.

If the government determines that vaccinations are essential to stemming the spread of the disease, would it– could it–mandate vaccination compliance? Apparently, it can—and it might.